The regenerative medicine industry is a high-value, fast-growth market. With two CAR-T approvals, as well as the first gene therapy and digital pill approvals in the United States, we have had a lot of FDA “firsts.” The market gathered momentum when the Swiss pharmaceutical giant Novartis made history as the first company to win FDA approval for a CAR-T cell therapy in the U.S. in August 2017 (Kymriah). In October 2017, Kite Pharma became the second company to get FDA approval of a CAR-T cell therapy (Yescarta), further “snowballing” the effect. [Read more…]
Best Cord Blood Banking Conferences
Cord blood conferences have been expanding in number and frequency over the past decade. Cord blood banking is the long-term storage and preservation of umbilical cord blood collected during the birth of a newborn. It is collected, because it is rich in hematopoietic stem cells (HSCs), a stem cell type that is widely used in transplant medicine and can be used to treat over 80 different conditions. The matrix of the umbilical cord, called Wharton’s Jelly, is also a rich source of mesenchymal stem cells (MSCs), a cell type that is now being explored in more than 800 clinical trials worldwide.
Each year, cord blood industry experts gather at these events to discuss trends, research progress, and clinical and technological advances.
Below, we highlight leading cord blood industry events, many of which BioInformant attends, sponsors, or helps to organize. [Read more…]
BioLamina and Novo Nordisk Partner to Advance Stem Cell Based Therapies
STOCKHOLM, May 16, 2018 — BioLamina and collaborators have partnered with Novo Nordisk A/S (Novo Nordisk), a Danish multinational pharmaceutical company, allowing Novo Nordisk to develop novel stem cell based therapies based on Biolaminins, human recombinant laminin cell culture matrices, developed and produced by BioLamina. [Read more…]
Market Players Developing iPS Cell Therapies
While a number of companies have dabbled in this space, the following players are leaders in the development of iPS cell therapies: Cellular Dynamics International (a Fujifilm Company), Cynata Therapeutics, RIKEN, and Astellas (previously Ocata Therapeutics).
iPS Cell Therapy Market Players
In this article:
- Cellular Dynamics International, Owned by FujiFilm
- Cynata Therapeutics
- RIKEN
- Astellas, Previously Ocata Therapeutics
Leading iPS Cell Therapy Companies
The four companies and organizations below are major innovators of iPSC therapeutics.
[Read more…]
Nohla Therapeutics Secures $45 Million to Develop Cord Blood Treatment for Leukemia
Nohla Therapeutics Announces Closing of $45 Million Series B Financing
Proceeds to Support the Development of Dilanubicel (NLA101) and Additional Platform Programs
Seattle, WA; May 15, 2018 – Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignances and other critical diseases, today announced the closing of a $45 million Series B financing. In this round, Fidelity Management and Research Company and Celgene Corporation (Nasdaq: CELG) joined existing investors, ARCH Venture Partners, 5AM Ventures, Alexandria Venture Investments and AML Biotech Partners, who also participated in the financing. [Read more…]
- « Previous Page
- 1
- …
- 239
- 240
- 241
- 242
- 243
- …
- 340
- Next Page »